Continuum of renoprotection with Losartan at all stages of type 2 diabetic nephropathy:: A post hoc analysis of the RENAAL trial results
Continuum of renoprotection with Losartan at all stages of type 2 diabetic nephropathy:: A post hoc analysis of the RENAAL trial results
复制标题
DOI：
10.1097/01.asn.0000146423.71226.0c
复制
发表时间：
2004-12-01
影响因子：
13.6
通讯作者：
Brenner, BM
中科院分区：
文献类型：
--
作者：
Remuzzi, G;Ruggenenti, P;Brenner, BM
肾素血管紧张素系统抑制剂治疗很少提供给患有糖尿病和晚期慢性肾脏疾病的人，因为安全问题。在这项使用血管紧张素II拮抗剂氯沙坦（RENAAL）试验降低NIDDM终点的事后、二次分析中，对1513例2型糖尿病和显性肾病患者进行了血管紧张素拮抗剂风险/获益评估。在氯沙坦或常规治疗期间，ESRD、心力衰竭住院、不良事件停药和蛋白尿的发生率在基线血清肌酐浓度的三分位数范围内进行比较（最高为2.1至3.6 mg/dl，中间为1.6至2.0 mg/dl，最低为0.9至1.6 mg/dl）。在最高、中、最低三分位数，氯沙坦分别降低了24.6%、26.3%和35.3%的ESRD风险。每100例患者血清肌酐bbb2.0, 1.6 ~ 2.0，或
Renin angiotensin system inhibitor therapy is seldom offered to individuals who have diabetes and advanced chronic kidney disease because of safety concerns. In this post hoc, secondary analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial, angiotensin antagonism risk/benefit profile was assessed in 1513 individuals with type 2 diabetes and overt nephropathy. Incidence of ESRD, hospitalizations for heart failure, withdrawals for adverse events, and proteinuria during losartan or conventional treatment were compared within three tertiles of baseline serum creatinine concentration (highest, 2.1 to 3.6 mg/dl; middle, 1.6 to 2.0 mg/dl; lowest, 0.9 to 1.6 mg/dl). Losartan decreased the risk of ESRD by 24.6, 26.3, and 35.3% in highest, middle, and lowest tertiles, respectively. For every 100 patients with serum creatinine >2.0, 1.6 to 2.0, or